SA prepares for potential new adult TB vaccine
Intelligence Summary
The Department of Health is gearing up for the potential introduction of a new adult TB vaccine, which would be the first in over a century. This is a significant public health development with procurement implications, including vaccine supply, distribution, and local manufacturing partnerships. While the vaccine is still in Phase 3 trials, the department's proactive preparation suggests that tenders for vaccine procurement and related services may emerge in the coming years, contingent on regulatory approval and funding.
Why This Matters for Procurement
This could lead to substantial government procurement of vaccines and related services, creating opportunities for pharmaceutical suppliers, logistics providers, and cold chain specialists. It also signals a shift in public health priorities towards TB elimination, which may influence budget allocations.
Key Points
- The Department of Health is preparing for the introduction of a new adult TB vaccine (M72/AS01E), currently in Phase 3 trials, which could lead to significant procurement of vaccines and related services.
- The agreement with the Serum Institute of India includes progressive local production in South Africa, creating opportunities for local pharmaceutical manufacturers and supply chain partners.
- Preparatory work for registration and introduction signals upcoming tenders for vaccine procurement, cold chain logistics, and distribution services.
- The vaccine, if approved, would be the first new TB vaccine in over a century, potentially shifting public health priorities and budget allocations.
- The department's proactive stance suggests a high likelihood of future procurement activity, but timelines depend on trial success and regulatory approval.
Industry Impact
The Department of Health has confirmed preparatory work for the introduction of a new adult TB vaccine, including an agreement for local production in South Africa.
Industry-Wide Effect
This development could stimulate the local pharmaceutical manufacturing sector and reduce reliance on imported vaccines. It may also set a precedent for future vaccine procurement and local production partnerships, impacting the broader public health procurement landscape in South Africa.
Affected Sectors
Affected Provinces
Affected Organs of State
Supplier Opportunity Signal
Suppliers in vaccine manufacturing, distribution, and cold chain logistics should monitor the Department of Health's procurement plans. Local pharmaceutical companies may benefit from technology transfer and local production agreements. Tenders for vaccine supply, storage, and distribution are likely to follow once the vaccine is approved.
Risk / Compliance Signal
Procurement must comply with the Preferential Procurement Policy Framework Act (PPPFA) and Treasury regulations. Bidders should ensure they meet local production requirements and quality standards. There may be risks related to intellectual property and technology transfer agreements.
From the Original Source
Excerpt reproduced for context. Tenders SA analysis is based on this public source. Read the full article at SAnews.gov.za.
Stay ahead of procurement changes